Preclinical Meta-Analysis of Moringa Oleifera for Peptic Ulcer Disease

Comprising the results of a systematic review and meta-analysis of 11 preclinical studies involving 268 animals, evaluating the therapeutic effect of Moringa oleifera extracts on peptic ulcer disease. It includes pooled analysis results such as standard mean difference (SMD), confidence intervals, p-values, and heterogeneity metrics (I²). The data was compiled by Saheed Olatunbosun Akiode and published on figshare in March 2026.

Use Cases

• Analyze the relationship between Moringa oleifera dose and the pooled standard mean difference (SMD) for ulcer index reduction.
• Assess methodological heterogeneity across studies using the reported I² values and SYRCLE quality scores (8-9).
• Compare the therapeutic efficacy of Moringa oleifera against standard drugs using subgroup analysis SMD results.
• Investigate publication bias in preclinical research using the Egger’s regression and trim-and-fill methods described.

Strengths

• Includes quantitative results from 11 eligible studies, providing a consolidated evidence base.
• Reports specific meta-analysis metrics: pooled SMD of -1.42 with 95% CI and p < 0.01.
• Contains subgroup analysis results comparing high-dose extracts to standard drugs and basal controls.
• Dataset is openly licensed under CC BY 4.0, facilitating reuse.

Limitations

• The dataset is very small (39.6 KB), containing only summary-level meta-analysis results, not raw study data.
• Findings are limited to preclinical (rodent) models and have not been validated in clinical trials.
• The original review notes methodological heterogeneity among the included studies.

Provenance

Source

Systematic review of PubMed, CINAHL, Scopus, Web of Science, and the Cochrane Library.

Collection Method

Random-effects meta-analysis performed using Hedge’s g to calculate standard mean difference (SMD).

Time Range

Literature search from database inception to August 2025.

Freshness

Last updated on 2026-03-20, with literature search up to August 2025.